AR040232A1 - Proceso para preparar inhibidores de la xantina fosfodiesterasa v, y precursores de los mismos - Google Patents

Proceso para preparar inhibidores de la xantina fosfodiesterasa v, y precursores de los mismos

Info

Publication number
AR040232A1
AR040232A1 ARP030101921A ARP030101921A AR040232A1 AR 040232 A1 AR040232 A1 AR 040232A1 AR P030101921 A ARP030101921 A AR P030101921A AR P030101921 A ARP030101921 A AR P030101921A AR 040232 A1 AR040232 A1 AR 040232A1
Authority
AR
Argentina
Prior art keywords
formula
compound
reacting
alkyl
group
Prior art date
Application number
ARP030101921A
Other languages
English (en)
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR040232A1 publication Critical patent/AR040232A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP030101921A 2002-05-31 2003-05-30 Proceso para preparar inhibidores de la xantina fosfodiesterasa v, y precursores de los mismos AR040232A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38447802P 2002-05-31 2002-05-31

Publications (1)

Publication Number Publication Date
AR040232A1 true AR040232A1 (es) 2005-03-23

Family

ID=29712039

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101921A AR040232A1 (es) 2002-05-31 2003-05-30 Proceso para preparar inhibidores de la xantina fosfodiesterasa v, y precursores de los mismos

Country Status (17)

Country Link
US (2) US7074923B2 (US07786301-20100831-C00010.png)
EP (1) EP1509525B9 (US07786301-20100831-C00010.png)
JP (1) JP2005529934A (US07786301-20100831-C00010.png)
CN (2) CN100497336C (US07786301-20100831-C00010.png)
AR (1) AR040232A1 (US07786301-20100831-C00010.png)
AT (1) ATE336494T1 (US07786301-20100831-C00010.png)
AU (1) AU2003238822A1 (US07786301-20100831-C00010.png)
CA (1) CA2483923A1 (US07786301-20100831-C00010.png)
CY (1) CY1105774T1 (US07786301-20100831-C00010.png)
DE (1) DE60307628T2 (US07786301-20100831-C00010.png)
DK (1) DK1509525T5 (US07786301-20100831-C00010.png)
ES (1) ES2270047T3 (US07786301-20100831-C00010.png)
HK (1) HK1068139A1 (US07786301-20100831-C00010.png)
MX (1) MXPA04011862A (US07786301-20100831-C00010.png)
PT (1) PT1509525E (US07786301-20100831-C00010.png)
WO (1) WO2003101992A1 (US07786301-20100831-C00010.png)
ZA (1) ZA200408719B (US07786301-20100831-C00010.png)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
NZ528216A (en) * 2001-02-24 2006-12-22 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
TW200404802A (en) * 2002-05-31 2004-04-01 Schering Corp Xanthine phosphodiesterase V inhibitor polymorphs
WO2004009091A1 (en) * 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) * 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
CA2533715A1 (en) 2003-07-31 2005-02-10 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
AR047948A1 (es) * 2003-11-21 2006-03-15 Schering Corp Formulaciuones de inhibidores de la fosfodiesterasa v
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) * 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) * 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2057160A1 (en) 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
KR101610005B1 (ko) * 2007-08-17 2016-04-08 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ 관련 질환의 치료에 사용하기 위한 푸린 유도체
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
EA031225B1 (ru) * 2008-08-15 2018-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы дпп-4 для заживления ран
EP2344195A2 (en) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) * 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
JPH0372480A (ja) * 1989-08-10 1991-03-27 Hokuriku Seiyaku Co Ltd キサンチン誘導体及びそれらを有効成分とする気管支拡張剤
CA2030112A1 (en) * 1989-11-24 1991-05-25 Yasuo Ito Xanthine compound, method for preparing thereof, and a pharmaceutical composition comprising the same
IL98559A0 (en) * 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
JPH04128285A (ja) * 1990-06-27 1992-04-28 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH04279586A (ja) * 1991-03-05 1992-10-05 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH051065A (ja) * 1991-06-20 1993-01-08 Hokuriku Seiyaku Co Ltd キサンチン誘導体
DE59208572D1 (de) * 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
DE4411660A1 (de) * 1994-04-05 1995-10-12 Hoechst Ag Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
ATE226583T1 (de) * 1996-06-07 2002-11-15 Hoechst Ag Verwendung von theophyllinderivaten zur behandlung und propylaxe von schockzuständen, neue xanthinverbindungen und verfahren zu deren herstellung
HUP0301622A3 (en) * 2000-07-04 2006-05-29 Novo Nordisk As Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
NZ528216A (en) * 2001-02-24 2006-12-22 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1421084B1 (en) 2001-08-28 2008-05-14 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
EP1463727A2 (en) * 2001-09-19 2004-10-06 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
EP1442042A1 (en) 2001-11-09 2004-08-04 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
ATE409466T1 (de) * 2002-01-11 2008-10-15 Novo Nordisk As Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
JP2004043429A (ja) * 2002-02-25 2004-02-12 Eisai Co Ltd 新規キサンチン誘導体およびｄｐｐｉｖ阻害剤
TW200404802A (en) * 2002-05-31 2004-04-01 Schering Corp Xanthine phosphodiesterase V inhibitor polymorphs
WO2004009091A1 (en) * 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
KR101150449B1 (ko) * 2002-08-21 2012-06-01 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 8-［3-아미노-피페리딘-1-일］-크산틴, 이의 제조방법 및 이를 포함하는 약제학적 조성물
AU2003269850A1 (en) * 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
AU2003280680A1 (en) * 2002-11-01 2004-06-18 Sumitomo Pharmaceuticals Co., Ltd. Xanthine compound
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
CA2533715A1 (en) * 2003-07-31 2005-02-10 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
US7074923B2 (en) 2006-07-11
CN100497336C (zh) 2009-06-10
CN1668618A (zh) 2005-09-14
DE60307628D1 (de) 2006-09-28
US20030232987A1 (en) 2003-12-18
CN101538224A (zh) 2009-09-23
WO2003101992A1 (en) 2003-12-11
EP1509525B1 (en) 2006-08-16
DK1509525T5 (da) 2007-07-30
EP1509525B9 (en) 2007-10-31
PT1509525E (pt) 2006-12-29
HK1068139A1 (en) 2005-04-22
JP2005529934A (ja) 2005-10-06
MXPA04011862A (es) 2005-03-31
ZA200408719B (en) 2005-11-15
CY1105774T1 (el) 2011-02-02
CA2483923A1 (en) 2003-12-11
EP1509525A1 (en) 2005-03-02
ES2270047T3 (es) 2007-04-01
DK1509525T3 (da) 2006-12-11
DE60307628T2 (de) 2007-08-09
US20060205943A1 (en) 2006-09-14
ATE336494T1 (de) 2006-09-15
US7786301B2 (en) 2010-08-31
AU2003238822A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
AR040232A1 (es) Proceso para preparar inhibidores de la xantina fosfodiesterasa v, y precursores de los mismos
AR064304A1 (es) Formulaciones de ansamicina y sus metodos de uso
PH12014502866A1 (en) Fungicidal heterocyclic carboxamides
PE20190705A1 (es) COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING
AR049263A1 (es) Heterociclos biciclicos inhibidores de quinasa utiles como agentes anticancer
PH12014501804A1 (en) Cycloalkane derivative
EA200600258A1 (ru) Триазолопиримидиновые производные в качестве ингибиторов киназы-3 гликогенсинтазы
BR112014008196B8 (pt) processo para a preparação de um composto da fórmula (i)
CO5690638A2 (es) Nuevos compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos; proceso para su preparacion y composiciones farmaceuticas que los contienen
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
DOP2005000046A (es) Compuestos de acido alfa arilo o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
AR095347A1 (es) Compuestos orgánicos
AR044856A1 (es) Acidos biariloximetilarenocarboxilicos; procedimientos para su preparacion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
EA201071078A1 (ru) Новые производные карбазола, являющиеся ингибиторами hsp90, содержащие их композиции и их применение
AR051642A1 (es) Derivados de purina; un metodo para su preparacion; composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos para el tratamiento de enfermedades mediadas por el receptor a2a de adenosina.
AR094646A1 (es) Morfinanos sustituidos y su uso
CY1122470T1 (el) Αναστολεις kv1.3 και η ιατρικη εφαρμογη αυτων
JP2017531041A5 (US07786301-20100831-C00010.png)
AR065249A1 (es) Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales.
KR960700226A (ko) 탁산유도체의 제조공정과 그 공정의 β-락탐 중간체들
HN2011003482A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)
PH12015502851A1 (en) Curable composition
HRP20210402T1 (hr) Spojevi
WO2014184272A3 (en) Chemical compositions for targeting isocitrate dehydrogenase and for treating cancer

Legal Events

Date Code Title Description
FB Suspension of granting procedure